AIDS-related lymphoma
Drug research and approvals for AIDS-related lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 10 studies of AIDS-related lymphoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 10
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Optimization of Antiretroviral Therapy in Patients With AIDS-Related LymphomaNCT07727642 · Not applicable · Shanghai Public Health Clinical Center · starts May 26, 2026
- AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP…NCT07649304 · Phase 1 · National Cancer Institute (NCI) · starts Jul 5, 2027
- T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)NCT06343311 · Phase 1 / Phase 2 · Estrella Immunopharma, Inc. · starts Jun 1, 2024
- Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman…NCT05907759 · Phase 2 · National Cancer Institute (NCI) · starts Jul 10, 2024
- Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related CancersNCT05663502 · Not reported · AIDS Malignancy Consortium · starts May 10, 2023
- Study of SGR-1505 in Mature B-Cell NeoplasmsNCT05544019 · Phase 1 · Schrödinger, Inc. · starts Apr 10, 2023
- A Registry Study on HIV-related LymphomaNCT05231135 · Not reported · Rotkreuzklinikum München gGmbH · starts Aug 25, 2021
- Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin LymphomaNCT05077527 · Phase 1 · AIDS Malignancy Consortium · starts Feb 13, 2025
- Natural History of KSHV-Associated Multicentric Castleman s DiseaseNCT04968288 · Not reported · National Cancer Institute (NCI) · starts Nov 17, 2021
Phase 2 12 of 23
- CyclophosphamideDNA inhibitor
- VincristineTubulin inhibitor
- PrednisoneGlucocorticoid receptor agonist
- DoxorubicinDNA topoisomerase II alpha inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- CytarabineDNA inhibitor
- CisplatinDNA inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- Yttrium y 90 ibritumomab tiuxetanB-lymphocyte antigen CD20 binding agent
- BleomycinDNA inhibitor
- SulfamethoxazoleBacterial dihydropteroate synthase inhibitor
Phase 1 or earlier 6
- TanespimycinHeat shock protein HSP90 inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- TisagenlecleucelB-lymphocyte antigen CD19 binding agent
- Bortezomib26S proteasome inhibitor
- Bryostatin 1
- Indium in 111 ibritumomab tiuxetan
How its trials ended
28 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 9 whose ending is known, 22% met their primary endpoint, 0% missed it and 78% stopped early.
- Completed, result not reported1139%
- Ongoing725%
- Stopped: other or unclear621%
- Met its primary endpoint27%
- Stopped: enrollment or feasibility14%
- Status unknown14%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA